Synthetic Biology Market, By Product, By Technology, By Application, By End User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

The Synthetic Biology Market size was valued at US$ 16,456.45 Million in 2024, expanding at a CAGR of 17.5% from 2025 to 2032.
The synthetic biology market is experiencing robust growth driven by advances in DNA synthesis, gene editing, and bioengineering technologies. It integrates biology and engineering principles to design and construct new biological parts, systems, and organisms for various applications, including healthcare, industrial biotechnology, agriculture, and environmental solutions. Increasing demand for sustainable bio-based products, cost-effective genetic tools, and precision medicine further accelerates market expansion. Companies are investing heavily in automation, AI-driven design, and cell-free systems to enhance productivity and innovation. Overall, synthetic biology is transforming global industries through innovation and sustainability.

Synthetic Biology Market- Market Dynamics

Advancements in Genetic Engineering and DNA Synthesis
Advancements in genetic engineering and DNA synthesis are major drivers fueling the demand for synthetic biology by enabling precise, scalable, and cost-effective manipulation of biological systems. Genetic engineering tools like CRISPR-Cas9, TALENs, and ZFNs allow targeted editing of DNA sequences, facilitating the creation of organisms with tailored traits. These improvements have accelerated research and commercialisation of gene therapies, personalised medicines, and synthetic bio-products such as vaccines and biofuels. DNA synthesis technologies have evolved drastically, making the production of synthetic genes and genomes faster and cheaper, which supports high-throughput design and testing of biological parts. Additionally, the multidisciplinary initiative includes major funding streams specifically dedicated to DNA synthesis infrastructure, alongside supporting multidisciplinary Synthetic Biology Research Centres, training programs, and a Synthetic Biology Seed Fund. According to the data published in March 2025 by UK Research and Innovation (UKRI), its “Synthetic Biology for Growth” programme includes a major stream on DNA synthesis infrastructure. It committed about £102 million for multidisciplinary programmes, DNA-foundries, and training.

Synthetic Biology Market- Segmentation Analysis:

The Global Synthetic Biology Market is segmented on the basis of Product, Technology, Application, End User, and Region.
The market is divided into five categories based on Product: Enzymes, Oligonucleotide/Oligo Pools and Synthetic DNA, Xeno-Nucleic Acids, Cloning Technologies Kits, and Chassis Organism. Enzymes form one of the largest and most essential product segments, as they facilitate DNA manipulation, molecular reactions, and bioprocessing workflows. Oligonucleotides/Oligo pools, and synthetic DNA represent another major segment, driven by rapid advancements in DNA synthesis technologies. On the other hand, xeno-nucleic acids (XNAs) are a growing niche segment, offering chemically modified genetic polymers with enhanced stability and functionality. Cloning technology kits streamline molecular cloning, vector construction, and genome editing processes, reducing technical barriers and accelerating R&D pipelines. Whereas, chassis organisms act as engineered microbial or mammalian hosts used to build synthetic biological systems.
The market is divided into five categories based on Technology: PCR Technology, NGS Technology, Bioprocessing Technology, Genome Editing Technology, and Other Technologies. Polymerase chain reaction (PCR) technology enables rapid amplification of DNA, making it essential for synthetic biology workflows. It supports gene cloning, sequence verification, mutagenesis, and DNA assembly. On the other hand, NGS provides high-throughput DNA and RNA sequencing, enabling deep analysis of engineered organisms, large oligo pools, and genome-scale experiments. Bioprocessing technologies support the production of biological molecules using engineered cells. This includes fermentation systems, downstream purification, automation, and bioreactor optimization. Whereas, technologies like CRISPR-Cas, TALENs, and zinc-finger nucleases allow precise editing of DNA in microbes, plants, and mammalian cells.

Synthetic Biology Market- Geographical Insights

The synthetic biology market shows significant geographical diversity, with North America leading as the dominant region. This is driven by a mature biotechnology ecosystem, robust R&D investment, and strong government funding, particularly in the U.S. and Canada. Europe is the second-largest market, with well-established biotech hubs in countries like Germany, France, and the UK. Investments in synthetic biology here focus on pharmaceutical development and sustainable industrial applications. Asia Pacific is the fastest-growing region, fueled by rapid economic growth, expanding R&D capabilities, and increasing government support in countries such as China, India, Japan, and South Korea. Other regions like Latin America and the Middle East & Africa are emerging markets, with growth driven by increasing government investments, infrastructure development, and others.

Synthetic Biology Market- Country Insights

The U.S. holds a pivotal position in the global synthetic biology market, accounting for a significant share. The U.S. market is propelled by strong federal support and substantial private investments, particularly in the pharmaceutical and biotechnology sectors focused on drug discovery, personalised medicine, and bio-based product development. Technologies such as PCR, genome editing, and AI integration for predictive modelling play critical roles in accelerating synthetic biology research and commercial applications. Moreover, the country benefits from leading biotech companies, cutting-edge academic research, and strategic collaborations that enhance innovation and commercialisation. For instance, in March 2024, Twist Bioscience Corporation rolled out a next-generation DNA synthesis platform that enables longer DNA sequences with significantly reduced error rates.

Synthetic Biology Market- Competitive Landscape:

The synthetic biology market's competitive landscape is characterised by rapid innovation, strong R&D investments, and strategic collaborations among leading biotechnology firms. The market is highly dynamic, with companies focusing on advancements in gene editing, synthetic DNA synthesis, genome engineering, and bio-manufacturing technologies to address diverse applications in healthcare, agriculture, industrial chemicals, and environmental sustainability. For instance, in November 2021, GenScript significantly expanded its gene synthesis production capabilities in the United States by launching a new fully automated facility in Piscataway, New Jersey, near its U.S. headquarters. Additionally, the market players invest heavily in automation, machine learning, and AI-driven synthetic biology platforms to enhance product scalability and reduce costs. The market features intense competition among established biotechnology companies, startups, research institutions, and contract service providers, all striving to capitalise on evolving synthetic biology capabilities and expanding commercial opportunities.

Recent Developments:

In February 2025, Illumina, Inc. introduced a comprehensive multi-omics roadmap that spans genomics, single-cell analysis, spatial transcriptomics, and CRISPR workflows, and includes a new multimodal data analysis platform.
In July 2023, GenScript doubled its cGMP manufacturing capacity for single-guide RNA (sgRNA) and non-viral DNA payloads with the addition of a state-of-the-art 400,000 sq. ft. cGMP facility in Zhenjiang, China.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SYNTHETIC BIOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Genscript
Illumina, Inc.
Codexis, Inc.
Amyris, Inc.
Bota Biosciences Inc.
New England Biolabs
Synthetic Genomics Inc.
Thermo Fisher Scientific, Inc.
Twist Bioscience Corporation
Novozymes A/S
Others

GLOBAL SYNTHETIC BIOLOGY MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032

Enzymes
Oligonucleotide/Oligo Pools and Synthetic DNA
Xeno-Nucleic Acids
Cloning Technologies Kits
Chassis Organism

GLOBAL SYNTHETIC BIOLOGY MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

PCR Technology
NGS Technology
Bioprocessing Technology
Genome Editing Technology
Other Technologies

GLOBAL SYNTHETIC BIOLOGY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Healthcare
Clinical
Non-clinical
Non-healthcare
Biotech Crops
Speciality Chemicals
Bio-fuels
Others
Others

GLOBAL SYNTHETIC BIOLOGY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Academic and Government Research Institutes
Biotechnology and Pharmaceutical Companies
Others

GLOBAL SYNTHETIC BIOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more